Semintra is the first antagonist of angiotensinII receptors in Veterinary oral solution form, suitable for the reduction of proteinuria associated with feline chronic kidney disease.
This product is no longer in stock
Mechanism of action has a specific and selective. Acts directly on the undesirable effects derived from the AT1 receptor activation, while preserving the benefits associated with AT2 receptor activation. In addition, an oral solution is very well accepted by cats, ensuring treatment compliance.
Indications for use :
Reduction of proteinuria associated with chronic kidney disease (CKD ) in cats.
Do not use during pregnancy or breastfeeding.
Do not use in case of hypersensitivity to the active substance or any of the excipients .
Special precautions for use in animals
The safety and efficacy of telmisartan not been verified in cats under 6 months.
It is considered good clinical practice to monitor blood pressure of cats receiving Semintra they are anesthetized .
Due to the mechanism of action of the medicinal product, transient hypotension may occur . In case of detected clinical signs of hypotension symptomatic treatment should be administered , for example, fluid .
As is known, with substances that act on the renin-angiotensin - aldosterone system (RAAS ) may be a slight decrease of erythrocyte count . During treatment should be monitored erythrocyte count .
Precautions to be taken by the person administering the medicinal product to animals
In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label.
Avoid contact with eyes. In case of accidental contact with eyes, flush with water .
Wash hands after using .
Pregnant women should be especially careful to avoid contact with the drug , because it has been observed that substances acting on the RAAS, such as Receptor Blockers Angiotensin (ARBs ) and ACE inhibitors (ACEI ) affect fetus during pregnancy in humans.
People with hypersensitivity to telmisartan or other sartans / BRA should avoid contact with the veterinary medicinal product .
Adverse reactions (frequency and seriousness)
The following mild and transient gastrointestinal signs ( in decreasing order of frequency) have rarely been observed in a clinical study : Intermittent mild regurgitation , vomiting , diarrhea or loose stools.
Very rarely been observed elevation of liver enzymes , which normalized within days of stopping treatment.
A recommended dose of treatment effects were observed attributable to the pharmacological activity of the drug that included blood pressure reduction and decreased erythrocyte count .
The frequency of adverse reactions should be classified under the following groups:
- Very often ( more than 1 animal per 10 presents adverse reactions during treatment )
- Frequently ( more than 1 but less than 10 animals per 100 )
- Infrequently (more than 1 but less than 10 animals per 1,000 )
- In rare cases (more than 1 but less than 10 animals per 10,000 )
- Rarely (less than 1 per 10,000 animals , including isolated cases) .
Use during pregnancy , lactation .
Has not been established Semintra security during reproduction, pregnancy and lactation in cats .
Do not use during pregnancy or lactation
Interaction with other medicinal products and other forms of interaction
During combination therapy with amlodipine at the recommended dose showed no clinical evidence of hypotension.
Dosage and route of administration
The recommended dose is 1 mg telmisartan / kg (0.25 ml / kg ) .
The drug should be administered once daily directly into the mouth or with a small amount of food.
Semintra is an oral solution and is well accepted by the majority of cats.
The solution should be given using the measuring syringe provided with the package. The syringe is set on the bottle and has a weight - kg scale .
Seal the bottle with the cap after administration .
To avoid contamination , use only the supplied syringe to administer Semintra .
Overdose ( symptoms , emergency procedures , antidotes ) , if necessary
After a dose of up to 5 times the recommended dose for 6 months showed no adverse reactions other than those mentioned in section 4.6 .
An overdose of the drug ( up to 5 times the recommended dose for 6 months ) resulted in marked reductions in blood pressure , decreases in erythrocyte count ( effects attributable to the pharmacological activity of the drug) and increases in blood urea nitrogen (BUN ) . These effects are rarely observed under clinical conditions .
However, in the case of occurrence of transient hypotension , symptomatic treatment to be administered , p. eg . fluid .
Pharmacotherapeutic group : Angiotensin II antagonists , simple , telmisartan
ATC vet code : QC09CA07
Telmisartan is a specific antagonist of the angiotensin II receptor ( AT1 type ) orally active that causes a decrease in mean arterial pressure in a dose dependent mammals including cat. In a clinical study in cats with chronic renal failure showed a reduction in proteinuria within the first 7 days after initiation of treatment.
Telmisartan displaces angiotensin II from its binding sites on the AT1 receptor subtype . Telmisartan selectively binds the AT1 receptor and shows no affinity for other receptors, including AT2 receptors AT or other less known. The AT1 receptor stimulation is responsible for the pathological effects of angiotensin II in the kidney and other organs associated with angiotensin II , such as vasoconstriction , sodium and water retention , increased synthesis of aldosterone and organ remodeling . The effects associated with AT2 receptor stimulation , such as vasodilation, natriuresis and inadequate cell growth inhibition , are not deleted. Receptor binding is of long duration, due to the slow dissociation of the binding telmisartan AT1 receptor. Telmisartan does not exhibit partial agonist activity at the AT1 receptor .
Hypokalemia is associated with CKD, telmisartan although not affect the excretion of potassium as shown in the clinical field study in cats.
No customer reviews for the moment.